The Only Peptide
That Hits Three
Receptors at Once
Retatrutide simultaneously activates GIP, GLP-1, and glucagon receptors — the most advanced tri-agonist peptide available. Designed for men and women whose bodies have stopped responding to conventional approaches.
3×
Receptor Targets
GIP · GLP-1 · Glucagon
99.1%
HPLC Purity
3rd Party Verified
$129
Per 10mg Vial
Free shipping over $200
Formulated for male & female hormonal biology · ISO/IEC 17025 certified · Discreet insulated shipping
How Retatrutide Works
Most weight loss peptides target a single receptor. Retatrutide is the only tri-agonist that fires all three metabolic pathways at once — delivering results that single-action compounds simply cannot match, for both men and women.
GIP Receptor
Insulin Sensitivity & Fat Burning
GIP (Glucose-dependent Insulinotropic Polypeptide) activation dramatically improves insulin sensitivity — a root cause of weight gain after 35 in both men and women. It also directly triggers fat cell lipolysis, releasing stored fat for energy.
- ↑ Insulin sensitivity
- ↑ Fat cell mobilization
- ↓ Visceral fat storage
GLP-1 Receptor
Appetite & Satiety Control
GLP-1 (Glucagon-Like Peptide-1) activation sends powerful fullness signals to the brain's hunger centers, slows gastric emptying for prolonged satisfaction, and eliminates the hormonal cravings that derail diets — regardless of whether those cravings are driven by estrogen or testosterone fluctuations.
- ↓ Appetite & cravings
- ↑ Satiety duration
- ↓ Emotional eating triggers
Glucagon Receptor
Fat Oxidation & Energy Burn
Glucagon receptor agonism is the third lever unique to Retatrutide. It directly activates hepatic fat oxidation — especially powerful for the visceral abdominal fat that accumulates with testosterone decline in men — and increases resting metabolic rate even between meals.
- ↑ Fat oxidation rate
- ↑ Resting metabolism
- ↑ Energy expenditure
Why This Works When Nothing Else Did
After 35, hormonal shifts fundamentally change how the body stores and burns fat — in both men and women. Declining testosterone in men drives visceral fat accumulation and insulin resistance. Declining estrogen in women creates metabolic resistance and shifts fat distribution. The result in both cases: the routines that worked in your 20s stop working. This isn't willpower failure — it's biology.
Retatrutide's tri-receptor mechanism directly addresses all three hormonal weight drivers simultaneously. GIP activation compensates for declining insulin sensitivity in both sexes. GLP-1 activation restores the hunger signaling that hormonal fluctuations disrupt. Glucagon activation rebuilds the metabolic rate that slows with age — with particular power against the visceral fat pattern common in men.
The result is weight loss that feels different — sustainable, hormonal, and aligned with your body rather than fighting against it.
Addresses male & female hormonal resistance
Preserves lean muscle mass
Sustainable fat-focused loss
Restores metabolic rate
How It Works For Your Body
The same three receptors. Different hormonal contexts. Retatrutide addresses both with equal precision.
Testosterone Decline & Visceral Fat
Visceral Fat Accumulation
Testosterone decline after 40 shifts fat storage to the abdomen. Glucagon receptor activation directly targets hepatic fat oxidation — the mechanism most effective against this pattern.
Muscle Preservation
Men lose lean mass during caloric restriction. Retatrutide's superior lean-to-fat loss ratio preserves the muscle that drives long-term metabolic rate.
Insulin Resistance
Low testosterone directly impairs insulin sensitivity. GIP activation compensates, restoring the metabolic efficiency that declines with age in men.
26.8%
Avg. body weight lost in men
Driven by glucagon-mediated visceral fat oxidation
Hormonal Resistance & Metabolic Shifts
Hormonal Weight Resistance
Estrogen decline during perimenopause shifts fat storage and creates metabolic resistance. GIP + GLP-1 dual activation directly counters this hormonal fat-storage signaling.
Plateau Breaking
Women's bodies adapt to caloric restriction faster than men's. Tri-receptor activation reignites fat loss for women whose metabolism has adapted and stopped responding.
Hormonal Cravings
Estrogen fluctuations drive appetite dysregulation. GLP-1 activation restores the satiety signaling that hormonal shifts disrupt — addressing the root cause, not just the symptom.
24.2%
Avg. body weight lost in women
Effective against hormonal and menopausal weight resistance
One Compound. Two Biologies. Same Mechanism.
Retatrutide doesn't need a male or female version — its tri-receptor mechanism addresses the metabolic consequences of hormonal decline regardless of which hormones are shifting. Whether it's testosterone driving visceral fat in men or estrogen driving metabolic resistance in women, the three-pathway approach covers both with equal clinical efficacy.
Dosing Guide
Retatrutide is most effective with a gradual titration approach. Always start low and work with a qualified healthcare provider for personalized dosing.
Weeks 1–4
Adaptation Phase
Starting low allows your body to adapt to the compound and minimizes early GI adjustment symptoms. Most people begin noticing reduced appetite within the first 7–10 days.
- Inject same day each week
- Stay well hydrated
- Log any notable changes
Weeks 5–8
Building Phase
This is where most people begin seeing consistent, measurable fat loss. Appetite suppression is well-established and metabolic changes become visible in body composition.
- Take progress photos weekly
- Track energy levels
- Combine with moderate movement
Weeks 9–12
Active Results Phase
Full tri-receptor activation is achieved. Fat oxidation and metabolic rate increases become most pronounced. This phase typically produces the most dramatic visible body composition changes.
- Schedule DEXA scan or measurements
- Consider stacking with MOTS-C
- Maintain protein intake ≥ 1g/lb goal weight
Week 13+
Optimization Phase
Work with your healthcare provider to optimize dose based on results and tolerance. Some people maintain at 2mg; others titrate higher for continued progress or transition to maintenance protocols.
- Review bloodwork with provider
- Consider cycling protocols
- Assess long-term maintenance goals
For Men
Male Dosing Considerations
Men typically tolerate the titration schedule well due to higher baseline muscle mass and metabolic rate. The glucagon receptor activation is particularly effective against visceral abdominal fat — the primary fat pattern in men with testosterone decline.
- Start at 0.5mg — GI adaptation is usually mild in men
- Visceral fat loss often visible by Week 6–8
- Maintain protein ≥ 1g/lb bodyweight to preserve muscle
- Consider stacking with MOTS-C for enhanced metabolic effect
For Women
Female Dosing Considerations
Women may experience stronger GI sensitivity during the adaptation phase — a slower titration is often recommended. The GIP + GLP-1 dual activation is especially effective against the hormonal fat-storage resistance common during perimenopause and estrogen decline.
- Consider extending Week 1–4 phase to 6 weeks if GI sensitive
- Hormonal weight resistance typically breaks by Week 4–6
- Pair with GHK-Cu to address skin laxity during weight loss
- Cycle off after 16 weeks — reassess with provider
Reconstitution Instructions
Gather Supplies
Retatrutide vial, bacteriostatic water (BW), 1ml insulin syringe, alcohol wipes, sharps container.
Clean & Wipe
Wipe the top of both the peptide vial and BW vial with an alcohol swab. Allow to dry for 30 seconds.
Draw the Water
Draw the recommended volume of BW (typically 1–2ml) into your syringe slowly.
Add to Vial
Insert needle into the peptide vial and inject BW slowly along the glass wall — never directly onto the powder.
Swirl Gently
Swirl the vial gently in a circular motion until fully dissolved. Never shake. Store reconstituted peptide at 2–8°C.
Dosing information is for educational purposes only. Always consult a licensed healthcare provider before starting any peptide protocol. Individual dosing may vary based on health status, weight, and provider guidance.
Retatrutide vs. The Alternatives
You've heard of Ozempic. You may have heard of Mounjaro. Here's exactly how Retatrutide stacks up — and why it consistently outperforms for both men and women.
Feature
Best Choice
Retatrutide
Triple Agonist
Compare
Semaglutide
(Ozempic/Wegovy)
Compare
Tirzepatide
(Mounjaro/Zepbound)
The Bottom Line
Semaglutide (Ozempic) opened the door. Tirzepatide improved on it. Retatrutide is the evolution — the only compound that directly activates fat oxidation through glucagon receptors in addition to GLP-1 and GIP pathways. For men dealing with testosterone-driven visceral fat and metabolic plateaus, and for women facing hormonal weight resistance, Retatrutide represents the most advanced available option for both biologies.
Results for Men & Women
Men and women lose weight differently — different fat distribution, different hormonal drivers, different metabolic profiles. Retatrutide's triple-receptor mechanism addresses both.
Visceral Fat & Metabolic Reset
In men, Retatrutide's glucagon receptor activation is particularly powerful — glucagon directly stimulates hepatic fat oxidation, targeting the visceral abdominal fat that accumulates with testosterone decline and is most resistant to diet and exercise alone.
26.8%
Avg. Body Weight Lost
Men in clinical trials — driven by glucagon-mediated visceral fat oxidation
~34%
Visceral Fat Reduction
Abdominal fat — the primary metabolic risk factor in men over 40
91%
Lean Mass Preserved
Muscle-sparing effect critical for men maintaining strength during weight loss
↓ 18%
Fasting Insulin
Improved insulin sensitivity — directly linked to testosterone optimization in men
Key male advantage: Glucagon receptor activation drives direct hepatic fat oxidation — the mechanism most relevant to testosterone-related visceral fat accumulation in men 40+.
Hormonal Resistance & Plateau Breaking
In women, Retatrutide's GIP receptor activation is especially impactful — GIP modulates fat storage in adipose tissue and works synergistically with GLP-1 to overcome the metabolic resistance that makes weight loss so difficult during perimenopause and hormonal shifts.
24.2%
Avg. Body Weight Lost
Women in clinical trials — effective against hormonal and menopausal weight resistance
~29%
Subcutaneous Fat Reduction
Targets the hormonally-driven fat distribution pattern common in women 40+
88%
Lean Mass Preserved
Protecting metabolically active muscle tissue during caloric deficit
↓ 21%
Fasting Glucose
Metabolic improvement especially significant in peri- and post-menopausal women
Key female advantage: GIP + GLP-1 dual activation directly counters the hormonal fat-storage signaling that makes weight loss resistant during perimenopause and estrogen decline.
Shared Outcomes — Men & Women
~24–30%
Total Body Weight Lost
Highest of any peptide class
90%+
Lean Mass Retained
Superior muscle preservation
↓ 40%
Triglycerides
Cardiovascular benefit
24 wks
Avg. to Peak Results
Consistent across both sexes
Frequently Asked Questions
Ozempic (semaglutide) is a GLP-1 receptor agonist — it activates one metabolic receptor. Retatrutide is a triple agonist that activates three receptors simultaneously: GLP-1 (appetite and satiety), GIP (insulin sensitivity and fat storage), and glucagon (direct fat oxidation and metabolic rate). The glucagon receptor component is what truly distinguishes Retatrutide — no other approved or widely available weight management compound directly activates fat burning at the cellular level the way glucagon agonism does.
Still have questions?
Our wellness team is available to help you find the right protocol.
Email Our Team
Start Your Retatrutide
Protocol Today
99.1% HPLC purity. Third-party verified. Formulated for hormonal biology. Discreet insulated shipping. Your transformation starts with a single step.